miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma

Approximately 20–30% of patients with metastatic renal cell carcinoma (mRCC) in first-line treatment with tyrosine kinase inhibitors (TKIs) do not respond due to primary resistance to this drug. At present, suitable robust biomarkers for prediction of a response are not available. Therefore, the aim...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancers (Basel)
Egile Nagusiak: Ralla, Bernhard, Busch, Jonas, Flörcken, Anne, Westermann, Jörg, Zhao, Zhongwei, Kilic, Ergin, Weickmann, Sabine, Jung, Monika, Fendler, Annika, Jung, Klaus
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6162741/
https://ncbi.nlm.nih.gov/pubmed/30201928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10090321
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak